Rhythm Pharmaceuticals Inc RYTM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:53 PM EDT
24.06quote price arrow down-0.77 (-3.10%)
Volume
433,417
52 week range
3.04 - 27.29
Loading...
  • Open24.78
  • Day High25.69
  • Day Low23.65
  • Prev Close24.83
  • 52 Week High27.29
  • 52 Week High Date08/15/22
  • 52 Week Low3.04
  • 52 Week Low Date05/20/22

Key Stats

  • Market Cap1.22B
  • Shares Out50.72M
  • 10 Day Average Volume1.76M
  • Dividend-
  • Dividend Yield-
  • Beta2.72
  • YTD % Change140.68

KEY STATS

  • Open24.78
  • Day High25.69
  • Day Low23.65
  • Prev Close24.83
  • 52 Week High27.29
  • 52 Week High Date08/15/22
  • 52 Week Low3.04
  • 52 Week Low Date05/20/22
  • Market Cap1.22B
  • Shares Out50.72M
  • 10 Day Average Volume1.76M
  • Dividend-
  • Dividend Yield-
  • Beta2.72
  • YTD % Change140.68

RATIOS/PROFITABILITY

  • EPS (TTM)-3.49
  • P/E (TTM)-6.89
  • Fwd P/E (NTM)-6.56
  • EBITDA (TTM)-191.588M
  • ROE (TTM)-64.22%
  • Revenue (TTM)13.41M
  • Gross Margin (TTM)92.05%
  • Net Margin (TTM)-1,310.60%
  • Debt To Equity (MRQ)17.52%

EVENTS

  • Earnings Date10/31/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). The Company’s lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. It is focused on the melanocortin-4...
David Meeker M.D.
Chairman of the Board, President, Chief Executive Officer
Hunter Smith
Chief Financial Officer, Treasurer
Yann Mazabraud
Executive Vice President, Head of International
Jennifer Chien
Executive Vice President, Head of North America
Address
222 Berkeley St Fl 12
Boston, MA
02116-3733
United States

Top Peers

SYMBOLLASTCHG%CHG
ACRS
Aclaris Therapeutics Inc
16.50-0.38-2.25%
KURA
Kura Oncology Inc
15.69-0.16-1.01%
RNA
Avidity Biosciences Inc
21.45-0.44-2.01%
GOSS
Gossamer Bio Inc
13.92+0.08+0.58%
IGMS
IGM Biosciences Inc
24.58-0.44-1.78%